- Home
- INAB vs MDAI Comparison
INAB vs MDAI Comparison
Compare INAB & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INAB | MDAI |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 51.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INAB | MDAI |
|---|---|---|
| Price | $1.08 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 36.4K | ★ 101.6K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.88 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,650,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $1.18 |
| 52 Week High | $2.73 | $2.97 |
Technical Indicators
Market Signals| Indicator | INAB | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 51.91 |
| Support Level | $0.96 | $1.51 |
| Resistance Level | $1.22 | $1.67 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.81 | 61.00 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.